Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Cardiovascular Systems Inc Issues Q3 2013 Guidance; Revenue Guidance Above Analysts' Estimates
Cardiovascular Systems Inc announced that for the third quarter of 2013, it expects revenue growth of 20% to 25% over the third quarter of 2012, to a range of $25.5 million to $26.5 million and net loss in the range of $(6.6) million to $(7.2) million, or loss per common share ranging from $(0.31) to $(0.34). According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $24.4 million, net income of $(6.7) and EPS of $(0.32) for the third quarter of 2013.
Latest Developments for Cardiovascular Systems Inc
- Cardiovascular Systems Inc Issues Q4 2013 Guidance In Line With Analysts' Estimates
- Cardiovascular Systems Inc Issues Q2 2013 Revenue Guidance Above Analysts' Estimates; Issues Q2 2013 Mixed Earnings Guidance
- Cardiovascular Systems, Inc. Issues Q1 2013 Guidance; Earnings Guidance Below Analysts' Estimates
- Cardiovascular Systems, Inc. Issues Q4 2012 Guidance; Earnings Guidance Below Analysts' Estimates
- Share this
- Link this
- Digg this
Follow Reuters